Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Muscular Dystrophies; Muscular Dystrophy, Duchenne | Phase 2/Phase 3 | ClinicalTrials |
| Depression; Depressive Disorder; Depressive Disorder, Major | Phase 2 | ClinicalTrials |
| Depression; Depressive Disorder; Depressive Disorder, Major; Diabetes Mellitus, Type 2 | Phase 4 | ClinicalTrials |
| Huntington Disease | Phase 3 | ClinicalTrials |
| Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Sclerosis | Phase 3 | ClinicalTrials |
| Huntington Disease | Phase 2 | ClinicalTrials |
| Muscular Dystrophies; Muscular Dystrophy, Duchenne | Phase 3 | ClinicalTrials |
| Colitis; Colitis, Ulcerative; Inflammatory Bowel Diseases; Intestinal Diseases; Ulcer | Early Phase 1 | ClinicalTrials |
| Depression; Depressive Disorder; Substance-Related Disorders | Phase 4 | ClinicalTrials |
| Sarcopenia | Phase 2 | ClinicalTrials |
| Huntington Disease | Phase 2 | ClinicalTrials |
| Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Sclerosis | Phase 2 | ClinicalTrials |
| Huntington Disease | Phase 2 | ClinicalTrials |
| Huntington Disease | Phase 2 | ClinicalTrials |
| Depression; Depressive Disorder | Phase 4 | ClinicalTrials |
| Substance-Related Disorders | Phase 4 | ClinicalTrials |
| Depression | Phase 3 | ClinicalTrials |
CONTENTS